Lung cancer
-
Urine tests that pick up biomarkers of cancer are one way scientists hope to diagnose the disease early, and MIT researchers have demonstrated a particularly promising example that could give efforts to diagnose early-stage lung cancer a huge boost.
-
Australian researchers have affirmed an unusual, almost paradoxical, observation that cancer patients with high body mass index tend to display greater survival rates than patients with average healthy weights.
-
A promising new cancer drug will soon enter phase 2 clinical trials, after finding success in animal models and preliminary human studies. Known as AMG 510, the drug targets a gene mutation that’s one of the most common causes of cancer.
-
In preclinical tests, scientists at Wistar Institute have developed a molecule that disrupts a protein complex vital to cancer cell survival.
-
A new study is suggesting a simple breath analysis can accurately predict whether lung cancer patients will positively respond to immunotherapy treatments.
-
A Google research initiative aimed at harnessing artificial intelligence to better model and predict lung cancer has shown promise in a newly published study, with the technology even outperforming certified radiologists in some regards.
-
In the body, mRNA molecules are in charge of instructing cells to produce specific proteins, and hijacking this natural system is emerging as a promising new way to treat a wide variety of illnesses. A new inhalable mRNA aerosol could be a potential new treatment for cystic fibrosis or lung cancer.
-
Success with chemotherapy is a trade-off against subsequent damage to otherwise healthy organs, but thanks to a chance meeting at the Hudson Institute in Melbourne, lung cancer patients could be looking at more effective chemo with fewer side effects.
-
New research led by Swansea University has found a novel way to wring more health benefits out of tea, by making quantum dots from tea leaves and using them to slow the growth of lung cancer cells.
-
A new study is suggesting that combining two currently available and approved drugs could successfully target nearly 85 percent of current lung cancers. With fewer side effects than traditional chemotherapy the treatment is set to move into a phase 2 human clinical trial within 12 months.
-
Scientists have uncovered a novel molecular signature for an aggressive form of lung cancer. These cancers were also found to produce specific metabolites that can potentially be identified in plasma samples, raising hopes that a diagnostic blood test for this condition can be developed.
-
While e-cigarette vapor certainly doesn't contain the same kinds of carcinogenic compounds as regular cigarette smoke there is a growing body of research to suggest “vaping” may have its own set of unique harmful effects.
Load More